The Foundation is an experienced collaborator with biotechs, pharma and health tech companies seeking to advance Parkinson's programs. Collaboration opportunities include sponsorship, in-kind contributions and strategic input.
Collaborate with Us
The Michael J. Fox Foundation (MJFF) and industry collaborators frequently work together to advance shared goals. Your scientific expertise and resources coupled with our robust patient community and unique position at the nexus of Parkinson’s research can move us closer to new treatments and a better quality of life for people living with Parkinson’s disease (PD).
Our Foundation provides a range of resources available to industry at no cost for research that is aligned with our scientific priorities. MJFF also offers diverse collaborations models: financial, in-kind and non-financial.
Whether you are an emerging or established biotech, a pharmaceutical company or a health tech start-up, with an established Parkinson's program or just entering the field, if you share our goal of helping Parkinson's patients through research, we want to hear from you. Contact email@example.com to connect with our staff.
Advancing Research and Therapeutic Development
Funding and Non-financial Resources
MJFF offers a range of resources that directly enable and speed your research.
MJFF brings stakeholders together in a pre-competitive manner to leverage shared resources and expertise across multiple parties to solve common challenges.
MJFF promotes knowledge-sharing and incorporates the latest scientific findings in our efforts to find a cure to PD.
Engaging Parkinson’s Disease Community
In addition, we offer ways your company and its employees can meet and engage with the Parkinson’s community.
Patient and Physician Education
Our Foundation produces a number of tools for patients, their loved ones and their physicians. These promote educational information about Parkinson’s disease, its symptoms and new therapies in the pipeline so they can make informed care and research participation decisions.
Parkinson’s Research Community
We provide curated events as an opportunity for industry, academics and investors to learn about the latest in Parkinson's research and development and to broadly share the message of our progress.
- Parkinson’s Disease Therapeutics Conference – The only conference dedicated to Parkinson’s drug development, our annual meeting gathers 300 science and business professionals to network and discuss advances in the field. Please note, the 2020 conference will not be held due to the COVID-19 pandemic.
- Parkinson’s Disease Therapeutics Webinars – This new series of free online events feature presentations and discussions from leaders in Parkinson’s research and therapeutic development.
Parkinson’s Community Events
MJFF’s community engagement opportunities aim to support and celebrate advances made in Parkinson’s research with the PD community.
Want to learn more about working with us?
Contact our Staff
Email us at firstname.lastname@example.org to connect with our staff.
Collaboration Case Studies
See our collaborations in action.
Investing in Early-stage Therapies
We fund high-risk, high-reward, early-stage therapeutic testing (pre-clinical and clinical) to help small companies build data packages that attract larger investors with resources to advance these projects.
Parkinson’s Disease Education Consortium
This consortium is an alliance of biotechnology and pharmaceutical firms that support our commitment to furnishing high-quality education resources for the Parkinson's community.
Parkinson’s Progression Markers Initiative
Sponsored by MJFF and supported by 26 industry collaborators, the PPMI study is building the most robust dataset and biospecimen library in Parkinson’s research — readily available for discovery and replication work.
Research Tools Consortium
Via this pre-competitive consortium, MJFF and industry collaborators work to better understand existing pre-clinical tools and their use in laboratory experiments, as well as to develop new tools to address unmet challenges.